Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- (-) Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- (-) Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- (-) Real-World Data
- (-) Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Audience
Display Only
Showing 31 Results
NPC Shares Input on CMS’ Data Collection Requirements
NPC comments offer input on CMS' approach to data collection that would inform the agency's implementation of provisions within the Inflation Reduction Act that enable government price-setting for…
The President’s victory lap on the success of price controls is premature
In a commentary published in the Sarasota Herald-Tribune, NPC's John M. O’Brien discusses the potential effects of new price controls and what the future holds for Medicare.
After 30 years of 340B, it's time for data and an honest conversation
In a commentary published in STAT, NPC's John M. O’Brien outlines why transparency is essential to assessing the true impact of 340B.
Characterizing health plan evidence review practices: how often, how different, and how comprehensive?
All health care decisions should be evidence-based. Until now, it has been relatively unclear what goes into health plan evidence reviews. How frequently do health plans update their specialty drug…
Avoiding Methodological Faults in Real-World Evidence
Researchers from Brigham and Women’s Hospital, Harvard Medical Center and NPC found that the potential for biased findings in RWE studies increases substantially in the absence of a rigorous and…
Health Budgets Should Cap Patient Harm
An NPC-RTI study provides guidance on quality metrics and practices that can help decision makers understand which budget cap features have the potential to lessen the impact on patient health and…
What’s In Your RWE Evaluation Toolbox?
Real-world evidence (RWE) – information collected from everyday health care experiences – is growing in availability, and many health care decision-makers are interested in understanding and using…
Online Tools to Synthesize Real-World Evidence of Comparative Effectiveness Research to Enhance Formulary Decision Making
The authors describe and compare the features and characteristics of five tools to evaluate real-world evidence studies and add clarity on what the tools provide.
NPC’s Research Informs Policy Conversations
NPC's work was broadly featured in the Journal of Managed Care & Specialty Pharmacy’s 12-part 25th anniversary series featuring “topics of significance” in managed care.
Are ACOs Optimizing Medication Use?
An article in JMCP revisits a 2014 NPC study that surveyed Accountable Care Organizations (ACOs) readiness to optimize medication use. The Reflection article summarizes changes to the ACO policy…
NPC Weighs in on NQF’s Draft Report on Patient-Reported Outcomes
The National Pharmaceutical Council (NPC) submitted comments to the National Quality Forum (NQF) regarding the Patient-Reported Outcomes: Best Practices on Selection and Data Collection draft…
Strategies to Optimize Medication Use
The Accountable Care Learning Collaborative (ACLC) hosted a webinar to discuss how value-minded organizations are integrating strategies to optimize medication use to lower costs and improve patient…
New Study Reveals Little Consistency in Evidence Cited by Commercial Health Plans for Specialty Drug Coverage
When the health care community talks about evidence-based medicine, it’s usually in the context of efforts to ensure clinicians are delivering treatments to patients that align with the best…
Six Ways to Make Real-world Evidence Methods More Transparent
Acceptance of studies based on “real-world data” remains limited, partly because the research methods used to generate usable evidence are not always transparent. That perception could change thanks…
Integrating Data for Better Care Management
To accelerate the ability of care management programs to use data to combat rising health care costs, while ensuring patient access to innovative treatments that can improve outcomes, NPC sponsored…
Patients on RWE: WIIFM? (What’s In It for Me?)
In an article published in The Patient, NPC and the National Health Council found that while most patients were initially unaware of real-world evidence (RWE) and its actual or potential uses,…
FDA’s Real-World Data and Evidence Framework Is a Good Step Forward
The U.S. Food and Drug Administration today released its framework for evaluating the potential use of real-world evidence (RWE) to help support the approval of a new indication for a pre-approved…
Real-World Data in the Current Health Care Environment
In this guest blog post, Dr. Eberechukwu Onukwugha of the University of Maryland School of Pharmacy's Department of Pharmaceutical Health Services Research explores the value of real-world data.
NPC at ISPOR 2018: Gathering and Curating Real-World Data
The use and importance of real-world evidence (RWE) in clinical decision-making has been frequently cited by Food and Drug Administration (FDA) Commissioner Dr. Scott Gottlieb, so it’s not surprising…